The use of recombinant human epidermal growth factor to promote healing for chronic radiation ulcer

Int Wound J. 2007 Sep;4(3):216-20. doi: 10.1111/j.1742-481X.2007.00332.x.

Abstract

This case report describes the first successful use of recombinant human epidermal growth factor (rh-EGF) in radiation-induced chronic wound of bone and skin which remains to be difficult to treat. Such wound on the chest of a 59-year-old female patient is presented lasting 3 years despite flap surgery and conventional treatment. The treatment with rh-EGF achieved healing within 16 weeks but further study to evaluate its potential for radiation-induced chronic wounds is warranted.

Publication types

  • Case Reports

MeSH terms

  • Breast Neoplasms / radiotherapy
  • Chronic Disease
  • Epidermal Growth Factor / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Radiation Injuries / complications
  • Radiation Injuries / drug therapy*
  • Recombinant Proteins / therapeutic use*
  • Ulcer / drug therapy*
  • Ulcer / etiology
  • Wound Healing

Substances

  • Recombinant Proteins
  • Epidermal Growth Factor